Target Audience

This activity is designed for managed markets pharmacists and case managers.

Learning Objectives

After completing this activity, participants should be able to:

• Describe the significant changes in the updated National Asthma Education and Prevention Program (NAEPP) guidelines for the diagnosis and management of asthma
• Recognize the burden of moderate to severe-persistent asthma on patient outcomes and the healthcare system
• Assess severity vs. control as per the new guidelines and how they influence management
• Apply the updated NAEPP guidelines in the ongoing management of moderate to severe-persistent asthma for improved patient outcomes

Credit Eligibility

To be eligible for documentation of credit, all participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: November 15, 2007 Expiration Date: November 27, 2008

Estimated time to complete: 1 Hour

There is no fee associated with this activity.

Lecture Components

The presentation slides, post-test, and evaluation are available as a click through via the menu at the top of each page of this educational activity.

CPE Accreditation

Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 hour credit (0.1 CEU) of continuing pharmacy education (ACPE #452-000-07-016-H01).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.

Case Manager Accreditation

This activity is approved for 1 hour of continuing education credit for case managers by the Commission for Case Manager Certification (CCMC).

Grant Support

Supported by an educational grant from Genentech Inc, and Novartis Pharmaceutical Corporation.

Participating Faculty

Presenter

Carlos A. Camargo, MD, DrPH
Associate Professor of Medicine and Epidemiology
Harvard Medical School
Boston, Massachusetts

Independent Clinical Reviewer

Michael H. Mellon, MD
Associate Clinical Professor, Pediatrics 
University of California San Diego School of Medicine    
La Jolla, California

Financial Disclosure and Conflicts of Interest  

According to the disclosure policy of Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity.  All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest.  If a conflict is identified, it is the responsibility of Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
 
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Camargo: Speaker’s honoraria—AstraZeneca, GlaxoSmithKline, Merck. Research Funding—AstraZeneca. Research Funding, principal investigator—GlaxoSmithKline, Merck, Novartis, Respironics (funds paid to Massachusetts General Hospital). Consultant—AstraZeneca, Dey, Novartis, Schering-Plough.

Dr. Mellon: Speaker’s honoraria—AstraZeneca, Schering-Plough; Consultant—AstraZeneca.

Planning Committee Randy Robbin and John Savage, Princeton CME; Rosemary Hodgson, Melissa Berman, William Kormos, and Rob Brosen, Princeton Media Communications have disclosed no relevant financial relationships with any commercial interests.

Princeton CME requires all faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.

The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.